{"schema_version":"secwatch.filing_event.v1","accession":"0001645666-25-000009","form_type":"8-K","ticker":"KZR","cik":"0001645666","company_name":"Kezar Life Sciences, Inc.","filed_at":"2025-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.292136+00:00","generated_at":"2026-05-24T05:50:19.088126+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Kezar Life Sciences: positive PORTOLA Phase 2a data; steroid-sparing remissions in AIH, cash $132M","bullets":["31% of zetomipzomib patients achieved CR + steroid taper ≤5 mg/day vs 12.5% placebo in ITT (n=24).","In steroid-dependent subgroup, 36% zetomipzomib CR + taper ≤5 mg/day vs 0% placebo; median response 27.6 weeks.","No Grade 4/5 AEs; injection site reactions most common; one placebo SAE (variceal bleed), two zetomipzomib SAEs (fever, flu).","FY2024 net loss $83.7M vs $101.9M in 2023; cash $132.2M at Dec 31, 2024.","Company plans to discuss with FDA to remove partial clinical hold and design registrational trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001645666-25-000009","json":"https://secwatch.observer/filing/0001645666-25-000009.json","markdown":"https://secwatch.observer/filing/0001645666-25-000009.md","text":"https://secwatch.observer/filing/0001645666-25-000009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645666/000164566625000009/0001645666-25-000009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645666/000164566625000009/kzr-20250325.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T05:50:19.088126+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}